Aspire Biopharma Advances Sublingual Aspirin for Heart Attack Treatment with FDA Pre-IND Submission
核心洞察
Aspire Biopharma submitted a Pre-IND meeting request to the FDA for its sublingual aspirin formulation targeting acute myocardial infarction treatment.
Clinical trial data demonstrated the sublingual formulation inhibits platelet aggregation in under two minutes, acting four to five times faster than chewed aspirin with statistical significance (p<0.02).
The company targets NDA submission in the first half of 2026 for a product addressing the 800,000+ annual heart attack cases in the U.S.
Aspire Biopharma Holdings (搜索) has submitted a Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration for its lead product candidate, a fast-acting sublingual aspirin formulation designed to treat suspected acute myocardial infarction. The November 3, 2025 submission represents a significant regulatory milestone as the company pursues a 505(b)(2) pathway toward potential FDA approval.
Clinical Trial Results Demonstrate Superior Speed
The company's confidence stems from breakthrough clinical trial results showing its sublingual formulation begins inhibiting platelet aggregation in under two minutes, acting approximately four to five times faster than chewed aspirin tablets. The randomized, crossover bioavailability trial assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational sublingual aspirin compared to chewed uncoated aspirin tablets in healthy adults.
"Our clinical data is not just promising; it's a breakthrough in MCI treatment," said Kraig Higginson, Interim CEO of Aspire Biopharma. "We demonstrated that our sublingual formulation begins to inhibit platelet aggregation in under two minutes, acting approximately four to five times as fast as chewed aspirin."
The study demonstrated significantly higher and more rapid mean plasma concentrations of acetylsalicylic acid, aspirin's active form, compared to chewed aspirin tablets (p<0.05). Lowered levels of serum thromboxane B2, a key biomarker for reduced platelet accumulation, were observed within the first two minutes after dosing with statistical significance (p<0.02).
Regulatory Pathway and Market Opportunity
The FDA responded positively to Aspire's Pre-IND request on November 13, 2025, stating it would provide written responses in lieu of a meeting no later than January 2, 2026. The Pre-IND meeting initiates formal dialogue with the FDA to gain agency guidance on clinical development strategy and confirm the proposed regulatory pathway.
The sublingual aspirin addresses a substantial market opportunity, targeting the 800,000+ people in the U.S. who suffer heart attacks annually. Higginson emphasized the clinical significance: "In a heart attack, every second saved translates to preserved heart muscle. We are eager to present this compelling evidence to the FDA and define an efficient path to bring this superior treatment to patients."
Technology Platform and Pipeline Development
Aspire's patent-pending sublingual delivery technology enhances pharmacokinetic performance of active pharmaceutical ingredients by increasing bioavailability and improving speed of onset. The company filed an omnibus patent application with the U.S. Patent and Trademark Office, seeking protection for its proprietary technology across various drug classes.
The company expanded its scientific team with Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida, whose expertise in mechanically facilitated cell-cell electrofusion is expected to assist in further developing the sublingual delivery technology.
Development Timeline and Strategic Outlook
Aspire targets NDA submission for its sublingual aspirin in the first half of 2026. The company is also advancing a sublingual ED medication program, with plans to finalize formulation and manufacture test product in H1 2026, followed by initiation of a Phase 1 pharmacokinetic clinical crossover study in mid-2026.
"Looking ahead, investors can see a clear line of sight to a series of major, value-driving catalysts," Higginson stated. "The most significant is our targeted NDA submission for sublingual aspirin in the first half of 2026, which aims to disrupt a multi-billion-dollar market."
The company participated in CPHI Frankfurt, engaging in strategic discussions with global pharmaceutical companies regarding technical collaboration and licensing opportunities. These discussions have led to several licensing opportunities currently under consideration.
Aspire's sublingual delivery technology can be applied to various active pharmaceutical ingredients spanning both small and large molecule therapeutics, nutraceuticals, and supplements, offering potential to improve effectiveness and reduce side effects by delivering drugs directly to the bloodstream while avoiding the gastrointestinal tract.